Cite

HARVARD Citation

    Dores, G. et al. (2021). Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel. American journal of hematology. 96 (9), pp. 1087-1100. [Online]. 
  
Back to record